(Q36719706)

15 August 2017

1 reference

title

Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice (English)

1 reference

15 August 2017

main subject

carbapenem antibiotic

0 references

3

Tobias Welte

1 reference

15 August 2017

2

Hartmut Derendorf

1 reference

15 August 2017

Olaf Burkhardt

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

8

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

237-256

1 reference

A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: the Alexander Project

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

The MYSTIC (meropenem yearly susceptibility test information collection) programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Extended-spectrum beta-lactamases and clinical outcomes: current data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Minimising antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Recent developments in carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem: a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem, the first of a new group of carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Properties and potential of ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem: review of a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem: a review of its use in the treatment of bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro activity of ertapenem against bacterial isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro antimicrobial activity of doripenem, a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Activity of ertapenem against Neisseria gonorrhoeae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

In vitro activity of ertapenem: review of recent studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Resistance in gram-negative bacteria: enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

First isolation of metallo-beta-lactamase-producing multiresistant Klebsiella pneumoniae from a patient in Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

VIM-1 Metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla(IMP-8) in a university medical center in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Pharmacokinetics of ertapenem in healthy young volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Pharmacokinetics of intramuscularly administered ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Intraabdominal tissue concentration of ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Comparative pharmacokinetics of the carbapenems: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Antimicrobial tissue concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem therapy for community-acquired pneumonia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Ertapenem versus Piperacillin-Tazobactam for Treatment of Mixed Anaerobic Complicated Intra-Abdominal, Complicated Skin and Skin Structure, and Acute Pelvic Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Safety and tolerability of ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.2.237

21 January 2018

Identifiers

DOI

10.1517/14656566.8.2.237

1 reference

15 August 2017

1 reference